

Trial Description

Title

Effects of oxytocin on patients with Borderline Personality Disorder

Trial Acronym

[---]*

URL of the trial

[---]*

Brief Summary in Lay Language

Main objective of the trial is to examine if oxytocin, compared to placebo shows any additional effect on the therapy achievements (outcome) of patients with borderline personality disorder, who receive an in-patient standard psychotherapy (Dialectical-behavioral-therapy, Marsha Linehan (2006)).
Secondary objectives :
Investigate if oxytocin compared to placebo enhances social trust and emotion recognition in patients with borderline personality disorder.
Comparison of the effects of Oxytocin on patients with BPD and major depression.

Brief Summary in Scientific Language

RCT. Two substudies (clinical and experimental). Main objective of the trial is to examine if oxytocin, compared to placebo shows any additional effect on the therapy achievements (outcome) of patients with borderline personality disorder, who receive an in-patient standard psychotherapy (Dialectical-behavioral-therapy, Marsha Linehan (2006)).
Secondary objectives :
Investigate if oxytocin compared to placebo enhances social trust and emotion recognition in patients with borderline personality disorder.
Comparison of the effects of Oxytocin on patients with BPD and major depression.

Do you plan to share individual participant data with other researchers?

[---]*

Description IPD sharing plan

[---]*

Organizational Data



- DRKS-ID: **DRKS00000604**
- Date of Registration in DRKS: **2010/11/19**
- Date of Registration in Partner Registry or other Primary Registry: [---]*
- Investigator Sponsored/Initiated Trial (IST/IIT): **yes**
- Ethics Approval/Approval of the Ethics Committee: **Approved**
- (leading) Ethics Committee Nr.: **307/10 , Ethik-Kommission der Albert-Ludwig-Universität Freiburg**

Secondary IDs

- EudraCT-Number: **2010-020956-69**
- BfArM-No.: **4036755**

Health condition or Problem studied

- ICD10: **F60.31 - [generalization F60.3: Emotionally unstable personality disorder]**
- ICD10: **F33.1 - Recurrent depressive disorder, current episode moderate**

Interventions/Observational Groups

- Arm 1: **Syntocinon-Spray (Novartis)**
active substance: Oxytocin
4x singel dose of 24 I.U. (before the experiments)
For the period of 8 weeks 3 x a day 20 I.U. (max. daily dose of 60 I.E.)
- Arm 2: **Placebo-Spray**
same dose as arm 1

Characteristics

- Study Type: **Interventional**
- Study Type Non-Interventional: [---]*
- Allocation: **Randomized controlled trial**
- Blinding: **Double or multiple blind**
- Who is blinded: [---]*
- Control: **Placebo**
- Purpose: **Other**
- Assignment: **Factorial**



Study Type: **Interventional**

Study Type Non-Interventional: [---]*

Allocation: **Randomized controlled trial**

Blinding: **Double or multiple blind**

Who is blinded: [---]*

Control: **Placebo**

Purpose: **Other**

Assignment: **Factorial**

■ Phase: **N/A**

■ Off-label use (Zulassungsüberschreitende Anwendung eines Arzneimittels): [---]*

Primary Outcome

- **Symptom severity (Borderline-Symptom-List, Bohus et al., 2007)**
- **Number of criteria in DSM-IV**
- **Severity of depression (Beck-Depression-Inventory, Hautzinger et al., 1994)**
- **Frequency of self-injury**
- **Dropout (early therapy termination)**

Secondary Outcome

- **Emotion recognition**
- **social trust**
- **rejection sensitivity**
- **tension**
- **interpersonel problems**
- **impulsivity**
- **disosiation**
- **mood**
- **eye-tracking**
- **cortisol**
- **heart beat frequency**

14 process messure Points

Countries of recruitment

■ **DE Germany**

Locations of Recruitment



Recruitment

- Planned/Actual: **Planned**
- (Anticipated or Actual) Date of First Enrollment: **2010/12/01**
- Target Sample Size: **250**
- Monocenter/Multicenter trial: **Monocenter trial**
- National/International: **National**

Inclusion Criteria

- Gender: **Both, male and female**
- Minimum Age: **18 Years**
- Maximum Age: **50 Years**

Additional Inclusion Criteria

- **Borderline personality disorder or major depression (clinical control group)**
- **18 - 50 years of age**
- **Mini Mental Status Test > 27 (capacity to consent)**

Exclusion criteria

- **chronic or acute somatic health problems**
- **Schizophrenia**
- **Bipolar affective disorder**
- **pregnancy**
- **breast feeding**
- **neurological disorder**
- **allergy to antidegradants**

Addresses

■ Primary Sponsor

Psychologisches Institut der Albert-Ludwigs-Universität Freiburg
Abteilung für Biologische und Differentielle Psychologie
Mr. Prof. Dr. Markus Heinrichs
Stefan-Meier-Str. 8
79104 Freiburg
Germany

Telephone: **0761-203-3029**

Fax: **0761-203-3023**

E-mail: **heinrichs at psychologie.uni-freiburg.de**

URL: **http://www.psychologie.uni-freiburg.de/**

■ Contact for Scientific Queries



Contact for Scientific Queries

Psychologisches Institut der Albert-Ludwigs-Universität Freiburg
Abteilung für Biologische und Differentielle Psychologie
Ms. Dipl.-Psych. Nicole Ower
Stefan-Meier-Strasse 8
79104 Freiburg
Germany

Telephone: **0761-203-97743**

Fax: **0761-203-3023**

E-mail: **Nicole.ower at psychologie.uni-freiburg.de**

URL: **<http://www.psychologie.uni-freiburg.de/>**

■ Contact for Public Queries

Psychologisches Institut der Albert-Ludwigs-Universität Freiburg
Abteilung für Biologische und Differentielle Psychologie
Ms. Dipl.-Psych. Nicole Ower
Stefan-Meier-Str. 8
79104 Freiburg
Germany

Telephone: **0761-20397743**

Fax: **0761-203-3023**

E-mail: **Nicole.ower at psychologie.uni-freiburg.de**

URL: **<http://www.psychologie.uni-freiburg.de/>**

Sources of Monetary or Material Support

■ Institutional budget , no external funding (budget of sponsor/PI)

Psychologisches Institut der Albert-Ludwigs-Universität Freiburg
Abteilung für Biologische und Differentielle Psychologie
Mr. Prof. Dr. Markus Heinrichs
Stefan-Meier-Str. 8
79104 Freiburg
Germany

Telephone: **0761-203-3029**

Fax: **0761-203-3023**

E-mail: **heinrichs at psychologie.uni-freiburg.de**

URL: **<http://www.psychologie.uni-freiburg.de/>**

Status

■ Recruitment Status: **Recruiting planned**

■ Study Closing (LPLV): **[---]***

DRKS-ID: **DRKS00000604**

Date of Registration in DRKS: **2010/11/19**

Date of Registration in Partner Registry or other Primary Registry: [---]*

Trial Publications, Results and other documents

* *This entry means the parameter is not applicable or has not been set.*

*** *This entry means that data is not displayed due to insufficient data privacy clearing.*